This inventor holds 3 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 2 EPO patents. Top assignee: Genzyme Corporation. Active years: 2019-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019-2025
Title: Matthew Adamowicz: Innovator in Gene Therapy for Macular Degeneration
Introduction
Matthew Adamowicz is an inventor based in Marlborough, MA (US). He is focused on developing innovative solutions in the field of gene therapy. His work aims to address significant health challenges, particularly in the area of age-related macular degeneration.
Latest Patent Applications
Matthew Adamowicz has submitted a patent application titled "Treatment of Dry Age-Related Macular Degeneration." This application presents a gene therapy approach that targets complement pathways for treating dry age-related macular degeneration. Although he currently has no granted patents, his research holds promise for future advancements in this critical area of healthcare.
Conclusion
Matthew Adamowicz is making strides in the field of gene therapy, particularly with his innovative approach to treating dry age-related macular degeneration. His contributions may pave the way for new treatments that can significantly improve the quality of life for those affected by this condition.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile